Michael J. Ginder
Partner @ Sands Capital Ventures
Arlington, United States
Michael J. Ginder is a Partner at Sands Capital Management.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Michael J. Ginder invests in
Stages Michael J. Ginder invests in
Countries Michael J. Ginder invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (100%)
- Pharmaceutical 3 (100%)
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Life Science 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Series D 1 (33%)
Country
- Israel 1 (33%)
- United States 1 (33%)
- United Kingdom 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics. | $76.5M / Series A / Oct 30, 2024 | ||
| Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs arefirst-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2) | $55.1M / Series D / Jul 11, 2022 | ||
| Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston. | $43M / Series B / Nov 03, 2021 |
Co-Investors
About Sands Capital Ventures
Sands Capital is an active, long-term investor in innovative growth businesses. The approach combines rigorous fundamental analysis with inspired thinking to seek out businesses that are creating the future. They operate through two affiliates: Sands Capital Management, which focuses on investing in companies in the public market, and Sands CapitalVentures, which focuses on investing in companies in the private market. By enabling clients to participate in the growth of these businesses, its mission is to add value and enhance their wealth with prudence over time.
Sands Capital Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Barron B. Martin, Jr.
Sr. Research Associate
|
|||
Christopher Eng
Principal
|
|||
Frank M. Sands, Jr.
Director
|
|||
Mark McGovern
Venture Partner
|
|||
|
Michael J. Ginder
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael J. Ginder invest in?
Michael J. Ginder invests primarily in Health Care, Pharmaceutical and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael J. Ginder?
Public channels for Michael J. Ginder include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael J. Ginder last invest?
The most recent investment recorded for Michael J. Ginder closed in Oct 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
